Search

Displaying results 5141 - 5150 of 10000 in total
  1. Drug

    IRX-5183

    go.drugbank.com/drugs/DB05653
    Investigational

  2. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

  3. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.

  4. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  5. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … Then, the medium is filtered and separated from the HUCBCs.

  6. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  7. Drug

    Imisopasem manganese

    go.drugbank.com/drugs/DB04976
    Investigational

    M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.

  8. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  9. Drug

    Iproclozide

    go.drugbank.com/drugs/DB09247
    ApprovedWithdrawn

    fatalities has resulted ultimately in the agent being discontinued. … Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported

  10. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.